Talk Around Town: A GSU Alumna's Startup Claims It Can Catch Failing ER Patients Before They Crash

What Folks Are Saying

Well, butter my biscuit and call me impressed — a startup called Teravus is out here saying it aims to fix one of the most quietly terrifying problems in American healthcare: patients sitting in emergency room waiting rooms getting sicker while nobody notices. According to Georgia State University's own news office, co-founder Miranda Baras says the company is developing what it describes as 'proprietary contactless biometric monitoring technology' designed to flag deteriorating patients before they hit the floor. The GSU profile, published June 29, 2026, is the loudest horn tooting this tune.

The company says — and that 'the company says' is doing a whole lot of heavy lifting here — that it's aiming its sights not just at hospitals but at public safety and defense technology sectors too, according to descriptions on the Teravus website and in founder interviews cited by GSU's news office. That's a wide net for a startup that, as of the same GSU profile, doesn't yet have a minimum viable product. It's a bit like announcing you're gonna win the county fair pie contest before you've located the oven.

What We Actually Know for Sure

Here's what's got enough corroboration to feel like solid ground beneath your boots. Baras is a confirmed 2022 graduate of Georgia State University's Biomedical Science and Enterprise master's program, and she co-founded Teravus as her capstone project while still enrolled, as reported by GSU's news office. That part checks out across multiple institutional sources going back to 2022.

Teravus participated in the University of Cincinnati's Venture Lab accelerator program, and both the UC and GSU institutional news outlets confirm the company received approximately $125,000 in seed funding from the UC Center for Entrepreneurship and Venture Lab. The UC's 2024 profile also confirms that Dr. Marvin Slepian — described there as a cardiologist and director of the University of Arizona Center for Accelerated Biomedical Innovation — joined the founding team through the Venture Lab program. A third co-founder, Jason Murray, is mentioned in the UC profile as the one who initially approached Venture Lab, though the GSU profile centers Baras as the primary entrepreneur. Both outlets are cheerleading for their own alumni, so sorting out who did what is like trying to judge a muddy-boot contest.

The University of Cincinnati's 2024 profile also confirms the personal origin story: according to that outlet, the inspiration for Teravus came from Baras's father, who experienced a health crisis after receiving delayed care in an emergency room. That's a real and well-documented problem in emergency medicine generally, even if the specific solution Teravus is pitching has not been independently evaluated.

What Nobody Has Verified Yet

Lord have mercy, the unverified pile is taller than a Georgia pine. Every single capability claim — that the contactless biometric monitoring technology actually works, that it can meaningfully detect patient deterioration, that it's technically differentiated from existing solutions — comes exclusively from the founders speaking through university PR offices. No independent technology journalists have poked at it. No peer-reviewed literature has evaluated it. No FDA filings are publicly visible. No third-party investors outside the UC Venture Lab have announced backing it.

The company's own website, as of the time of sourcing, shows only a brief self-description calling Teravus an 'innovative healthcare technology startup dedicated to revolutionizing the healthcare industry' — which is the kind of language that gets printed on motivational posters at startup weekends. The site is essentially a 'Coming Soon' splash page. Teravus says it has been testing hardware at a facility called ACABI, per the June 2026 GSU profile, but that claim originates with Baras herself and has not been confirmed by any independent party.

The broader claim that the technology is headed for defense and public safety applications, as described by the company, is also entirely self-reported. Whether the underlying biometric monitoring approach is novel or technically sound compared to existing hospital-grade patient monitoring systems is a question that no outside engineer, clinician, or analyst has weighed in on publicly.

Analysis: The Gap Between Story and Product

This is analysis, not reporting, so put on your thinking overalls. The core problem Teravus is aiming at — patients silently deteriorating in ER waiting rooms — is genuinely serious and well-documented in emergency medicine literature independent of anything the founders have said. That gives the mission some credibility as a target, even if the solution remains unproven. A startup chasing a real, painful problem with a founder who has personal skin in the game is at least starting on fertile soil.

But there's a significant distance between a compelling origin story and a commercially viable medical device. Teravus is, by Baras's own acknowledgment as reported by GSU's news office, still without an MVP, still raising funds, and still being run alongside the founder's separate full-time healthcare administration job. That's not a criticism — most early-stage startups look exactly like this — but it does mean the story being told right now is almost entirely about potential, not performance.

The sourcing situation is, to put it gently, thinner than a screen door on a submarine. Every meaningful claim traces back to the founders talking to institutional outlets that have an incentive to celebrate their alumni. Until independent engineers, clinicians, or investors weigh in, the contactless monitoring capability described by the company should be treated as an aspiration, not an established fact. The folks with the most to gain from this narrative are the ones telling it.